ECO Animal Health Group

What ECO Animal Health Group does

ECO Animal Health Group plc is a publicly listed UK-based animal health biotechnology company that develops, registers, and markets branded veterinary pharmaceuticals and biological products for pigs and poultry. Its lead product is Aivlosin® (sold as Valosin® in some markets), a proprietary patented antibiotic effective against both respiratory and intestinal diseases. The company's first internally developed vaccine, ECOVAXXIN® MS (targeting Mycoplasma synoviae in chickens), received European Commission marketing authorization in December 2025 and is being rolled out across the EU throughout 2026 and 2027. A second vaccine candidate, ECOVAXXIN® MG (targeting Mycoplasma gallisepticum), has progressed to US regulatory engagement following a favorable USDA safety assessment in March 2026.

The company operates a distribution-led, asset-light commercial model, selling through networks of skilled distributors and channel partners in over 70 countries rather than through direct sales forces at scale. Its customer base is horizontal, serving pig and poultry producers globally via two primary use-case segments. Pricing is not publicly disclosed, and revenue is generated through product sales with distribution agreements recently secured covering markets with over 220 million layer birds annually across the EU's seven largest layer-producing countries. ECO is described as profitable, headquartered in Southgate, London, listed on the London Stock Exchange (ticker: EAH), and maintains £15 million in total banking facilities with NatWest (a £10 million revolving credit facility through June 2031 plus a £5 million overdraft), all of which were unused at renewal.

ECO's core competency is upstream R&D and regulatory navigation, with downstream commercialization executed via partners. Recent strategic emphasis has been on converting the proprietary vaccine pipeline into revenue, with EU rollout of ECOVAXXIN® MS expected to be immediately margin-accretive and to contribute materially to EBITDA in the 2027/2028 financial year. US market entry via ECOVAXXIN® MG is targeted for regulatory submission in late 2027.

Name

ECO Animal Health Group

Legal name

ECO Animal Health Group plc

Website

https://ecoanimalhealthgroupplc.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

101–250 employees

Short description

ECO Animal Health Group plc is a UK-listed animal health biotech that develops and markets branded veterinary pharmaceuticals and vaccines for pigs and poultry, distributing through partners in over 70 countries with a lead proprietary antibiotic (Aivlosin®) and a newly commercialized vaccine pipeline.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Antimicrobials & Anti-infectives (HLAMAEAE), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Poultry vaccines
• Swine antibiotics
• Livestock disease treatment

Headquarters

HQ city

New Malden

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Veterinary Pharmaceuticals Sales: Sale of branded veterinary pharmaceutical products including antibiotics (Aivlosin®/Valosin®) and vaccines (ECOVAXXIN® MS, ECOVAXXIN® MG) for pigs and poultry. The company operates globally through distribution networks in over 70 countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

ECO Animal Health Group develops and markets branded veterinary pharmaceuticals for pigs and poultry, with expertise in antibiotics and vaccines. Its lead product Aivlosin® is a proprietary, patented antibiotic medication effective against respiratory and intestinal diseases, complemented by the emerging ECOVAXXIN® vaccine family (ECOVAXXIN® MS and ECOVAXXIN® MG) targeting poultry diseases such as Mycoplasma synoviae and Mycoplasma gallisepticum.

Product overview

ECO Animal Health is a profitable animal health biotech company that develops and markets branded veterinary pharmaceuticals for pigs and poultry, with expertise in antibiotics and vaccines. The portfolio consists of Aivlosin®/Valosin® as the lead pharmaceutical product for treating respiratory and intestinal diseases, supplemented by the ECOVAXXIN® vaccine family (ECOVAXXIN® MS and ECOVAXXIN® MG) targeting poultry diseases. The company focuses on economically important respiratory and enteric diseases, adding value to customers and enhancing profitability through a global network of partnerships across over 70 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Aivlosin®/Valosin® Proprietary, patented antibiotic medication effective against both respiratory and intestinal diseases in pigs and poultry. Sold in some markets under the tradename Valosin®.
• ECOVAXXIN® MS Live attenuated poultry vaccine for the control of Mycoplasma synoviae in chickens. First product from ECO's proprietary R&D pipeline to reach commercialization.
• ECOVAXXIN® MG

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Phibro Animal Health: Publicly listed animal health and nutrition company specializing in livestock pharmaceuticals, vaccines, and mineral nutrition. Comparable as a mid-cap competitor focused on production animal health, with a similar species-centric approach.
• Huvepharma: Specialist animal health and nutrition company focused on livestock pharmaceuticals and vaccines. Comparable as a focused livestock health player with a similar mix of proprietary pharmaceuticals and expanding biologics pipeline.
• Vetoquinol: Independent global animal health company with a strong livestock pharmaceuticals portfolio. Comparable in size and business model to ECO, with overlap in species focus and reliance on proprietary branded products.
• Virbac: Independent global animal health company with both livestock and companion animal offerings. Comparable in being an independent, mid-sized animal health specialist with a branded pharmaceutical and vaccine portfolio.
• Ceva Santé Animale: Private global animal health company focused on pharmaceuticals and vaccines for livestock (including poultry and swine). Closely comparable business model and species focus to ECO, with similar reliance on biologics pipeline growth.

Emerging players

• IDT Biologika: Specialist veterinary vaccine manufacturer with focus on livestock (including poultry) biologics. Comparable in focus on livestock vaccines and biologics innovation, though smaller and with narrower species scope than ECO.

Broad incumbents

• Zoetis: World's largest pure-play animal health company with broad pharmaceutical and vaccine portfolios across livestock and companion animals. Highly comparable as a competitor in livestock antibiotics and poultry vaccines, but at vastly greater scale and species breadth.
• Boehringer Ingelheim Animal Health: Top-tier animal health player with leading swine and poultry vaccine franchises. Directly comparable as a competitor in livestock biologics and respiratory/enteric disease control, especially in EU markets.
• Elanco Animal Health: Major global animal health company with significant livestock pharmaceutical and vaccine franchises. Direct overlap in swine and poultry therapeutics and biologics, though Elanco serves many more species and geographies.
• MSD Animal Health (Merck Animal Health): Animal health division of Merck, one of the largest producers of livestock vaccines and pharmaceuticals globally. Overlaps directly with ECO in poultry vaccines (e.g., Mycoplasma) and swine therapeutics, with much broader portfolio and R&D resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ECO Animal Health Group